Grail secured about $325 million in a private placement to fund commercial expansion, reimbursement efforts and its planned regulatory push for multi-cancer early detection tests. The financing attracted institutional and strategic investors as the company prepares to scale sales and pursue regulatory filings. Management said proceeds, together with prior commitments, will extend the company’s runway into 2030 and support ongoing efforts to secure reimbursement and market access across screening programs.